Expedition Therapeutics - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeExpedition Therapeutics
Expedition Therapeutics logo

Expedition Therapeutics

0 followers

About Expedition Therapeutics

Expedition Therapeutics is a biotech company focused on developing novel oral therapies for inflammatory and respiratory diseases, most notably a next‑generation DPP1 inhibitor (EXPD‑101) for chronic obstructive pulmonary disease (COPD). The firm aims to address neutrophilic inflammation, a key driver of lung tissue damage, and is advancing its lead candidate through Phase 2 trials with plans to expand into related neutrophil‑driven conditions.

Recent News

No recent news for this company.

Recent Deals

Key Team Members

Henry van den Bedem, PhD

Chief Technical Officer

Roli Khattri, PhD

SVP, Head of Immunology

Dylan Mitchell, PhD

Head of Proteomics

Yuta Naro, PhD

Head of Bifunctional Discovery

Marie Yurkovich, PhD

Head of Strategy & Operations, Co-Founder

Key Facts

HQ Location

United States

Founded

2024

Employees

1 - 10

Status

Private

Website

https://expeditiontx.com